Canaccord and Octopus disclose stakes in Advanced Medical Solutions

  • Canaccord disclosed 9,356,517 Advanced Medical Solutions shares under Rule 8.3.
  • The holding represented 4.2375% as of 2 September 2026.
  • Octopus previously reported 7.23%, while Canaccord earlier reported 4.2498%.

Canaccord Genuity Wealth Limited and OCTOPUS INVESTMENTS LTD separately disclosed interests in Advanced Medical Solutions Group PLC under Rule 8.3 of the Takeover Code. In a disclosure dated 3 September 2026, Canaccord reported 9,356,517 5p ordinary shares, representing 4.2375%, as of 2 September, after previously reporting 9,383,857 shares, or 4.2498%, as of 28 August. The later filing recorded sales of 2,320 shares at 280.5599 pence and 4,920 at 281.08 pence. Octopus previously reported 15,953,578 shares, or 7.23%, alongside sales and an in-specie transfer of 350 shares. Both firms reported no derivatives, subscription rights, short positions, or related dealing arrangements.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.